Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.

Benzinga Newsdesk www.benzinga.com Negative 78.3%

Neg 78.3% Neu 0% Pos 0%

Comments

No comments yet. Be the first!